Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: tom jones who wrote (2560)	5/6/1999 10:49:00 PM
From: TomOrt	Read Replies (2) \| Respond to of 4676

antisense abstract; library.biotech.nature.com May 1999 Volume 17 Number 5 pp 476 - 479 Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides Sayon Roy1, Kathy Zhang1, Timothy Roth2, Sergei Vinogradov3, Richard S. Kao1 & Alexander Kabanov3 1. Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114. 2. University of Massachusetts Medical School, Worcester, MA 01655. 3. University of Nebraska Medical Center, Omaha, NE 68198. Correspondence should be addressed to S Roy. e-mail: sayon@vision.eri.harvard.edu We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothiocyanate-labeled FN-oligonucleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% 7.9% of control (p<0.05) at day 2, and 46.7% 4.9% of control (p<0.01) at day 6. In contrast, the -actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy. Keywords: gene therapy, antisense oligonucleotides, basement membrane, block copolymer